Abstract
RhoA/Rho-kinase (RhoA/ROK) pathway promotes vasoconstriction by calcium sensitivity mechanism. LPS causes nitric oxide (NO) overproduction to induce vascular hyporeactivity. Thus, we tried to examine the role of RhoA/ROK and NO in the regulation of vascular reactivity in different time-point of endotoxaemia. Male Wistar rats were intravenously infused for 10 min with saline or E. coli endotoxin (lipopolysaccharide, LPS, 10 mg/kg) and divided to five groups (n = 8 in each group): (i) Control, sacrificed at 6 h after saline infusion; (ii) LPS1h, sacrificed at 1 h after LPS infusion; (iii) LPS2h, sacrificed at 2 h after LPS infusion; (iv) LPS4h, sacrificed at 4 h after LPS infusion; and (v) LPS6h, sacrificed at 6 h after LPS infusion. LPS1h and LPS2h were regarded as early endotoxaemia, whereas LPS4h and LPS6h were regarded as late endotoxaemia. Indeed, our results showed that LPS reproduced a biphasic hypotension and sustained vascular hyporeactivity to noradrenaline (NA) in vivo. Interestingly, this hyporeactivity did not occur in ex vivo during early endotoxaemia. This could be due to increases of aortic RhoA activity (n = 5, P<0.05) and myosin phosphatase targeting subunit 1 phosphorylation (n = 3, P<0.05). In addition, pressor response to NA and vascular reactivity in early endotoxaemia were inhibited by ROK inhibitor, Y27632. Furthermore, plasma bradykinin was increased at 10 min (24.6±13.7 ng/mL, n = 5, P<0.05) and aortic endothelial NO synthase expression was increased at 1 h (+200%. n = 3, P<0.05) after LPS. In late endotoxaemia, the vascular hyporeactivity was associated with aortic inducible NO synthase expression (n = 3, P<0.05) and an increased serum NO level (n = 8, P<0.05). Thus, an increased RhoA activity could compensate vascular hyporeactivity in early endotoxaemia, and the large NO production inhibiting RhoA activity would lead to vascular hyporeactivity eventually.
Highlights
Vascular reactivity is mainly associated with smooth muscle contractility which is dually regulated by cytoplasmic Ca2+ concentration and Ca2+ sensitivity
The animals in LPS groups showed significantly progressive increases in heart rate (HR), ALT, CRE, blood urea nitrogen (BUN), lactate dehydrogenase (LDH) and nitric oxide (NO) during the experimental period (n = 8 in each groups, P,0.05), whereas LPS caused a biphasic change on blood pressure, including an immediate and transient fall in mean arterial pressure (MAP) (,60 mmHg at 30 min) and a sustained decline from 2 h (10163 mmHg) to 6 h (6864 mmHg), which was accompanied by a significant increase in HR during the experimental period
LPS (i) induced a biphasic hypotension, (ii) caused a sustained decrease of the pressor response to NA in vivo and vascular hyporeactivity to NA ex vivo in late endotoxaemia only, (iii) increased aortic RhoA activity and myosin phosphatase targeting subunit 1 (MYPT1) phosphorylation to maintain pressor response to NA and vascular reactivity which was inhibited by Y27632, and transiently increased plasma BK level and aortic endothelial NO synthase (eNOS) expression in early endotoxaemia, and (iv) increased the serum NO level associated with aortic inducible NO synthase (iNOS) expression and decreased aortic RhoA activity and MYPT1 phosphorylation in late endotoxaemia
Summary
Vascular reactivity is mainly associated with smooth muscle contractility which is dually regulated by cytoplasmic Ca2+ concentration and Ca2+ sensitivity. The pathway of RhoA/Rhokinase (RhoA/ROK) is the major cellular target for regulating Ca2+ sensitivity of agonist-induced contraction (including a1adrenergic agonist) [1,2]. The activation of RhoA leads to stimulation of ROK that can phosphorylate and subsequently inactivate myosin light chain (MLC) phosphatase (MLCP), favoring MLC phosphorylation, actin-myosin interaction and cell contraction [3,4,5]. MLCP consists of a catalytic 38-kDa PP1c, an associated 110- to 130-kDa myosin phosphatase targeting subunit 1 (MYPT1) and a tightly bound 20-kDa subunit of unknown function [6]. MYPT1 is responsible for binding to PP1c and targeting myosin. Two phosphorylated sites of MYPT1 (at Thr696 and Thr850) have been proposed for the in situ inhibition of MLCP via Ga12/13/RhoA/ROK pathway [7,8,9,10,11]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have